Nyxoah SA NYXH 深 沪
等待开盘 10-23 09:30:00 美东时间
0.822
-0.073
-8.16%
华盛通- 最 高0.8619
- 今 开0.85
- 成交量 64.37万股
- 最 低 0.8011
- 昨 收 0.895
- 总市值 8371.27万
- 52周最高 5.92
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 0.8011
- 委 比 45.50%
- 总股本 1.02亿
- 历史最高 37.00
- 量 比 1.88
- 振 幅 6.79%
- 历史最低 0.8011
- 每 手 1
- 风险率 1.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NYXH收跌6.72%，成交额23.8万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:03
Nyxoah names new CEO
Nyxoah (NYXH) appointed Liam Kelly as chief executive officer, effective October 1, 2026, succeeding Olivier Taelman. The leadership change comes as Nyxoah transitions toward a U.S.-focused commercial...
09-29 04:49
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah appoints Liam Kelly as Chief Executive Officer, effective October 1, 2026, to strengthen its U.S. presence following FDA approval and the launch of Genio. Kelly brings over 25 years of leadership experience, previously serving as CEO and Chairman of Teleflex Incorporated. Nyxoah focuses on developing innovative solutions for Obstructive Sleep Apnea (OSA), with Genio as its lead product. The appointment underscores the company's strategic s...
09-28 20:30
Nyxoah names Loïc Moreau as interim CFO
Nyxoah (NYXH) said on Monday it appointed President International and former CFO Loïc Moreau as interim CFO, succeeding John Landry, effective Oct. 2, 2026. Moreau brings more than 20 years of finance...
09-22 04:16
Nyxoah Appoints Loic Moreau As Interim CFO, Effective Oct. 2, Succeeding John Landry; Reiterates FY26 Revenue Range Of €36M - €40M
Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role eff...
09-22 04:02
CVRx Appoints John Landry as Chief Financial Officer
CVRx appoints John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry, with over two decades of experience in medical device finance, joins from Nyxoah SA and previously led Vapotherm's IPO. He will support CVRx's growth, particularly in scaling Barostim, its FDA-approved neuromodulation therapy for heart failure patients. Oasheim is thanked for his contributions since 2015, including leading the company's IPO.
09-21 20:07
Nyxoah Announces Chief Financial Officer Transition
Nyxoah announced that John Landry will step down as Chief Financial Officer on October 2, 2026, to pursue another opportunity. Loïc Moreau, the Company’s President International and former CFO, will serve as Interim CFO. Nyxoah reaffirmed its full year 2026 financial guidance, expecting net revenue of €36-40 million, gross margin of 60-62%, and operating expenses of €99-102 million. The Company is focused on developing innovative solutions for Ob...
09-21 20:01
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
Nyxoah announced that its ACCCESS U.S. pivotal study for the Genio system met primary safety and efficacy endpoints in patients with Complete Concentric Collapse (CCC) of the soft palate. The study achieved a 77.2% AHI responder rate and 87.7% ODI responder rate at 12 months, with no device-related serious adverse events. These results support the expansion of Genio’s U.S. indication for CCC patients, who currently lack access to hypoglossal nerv...
09-02 20:05
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
